Effects of Low-Dose and Long-Term Treatment With Erythromycin on IL-17, IL-23 in Peripheral Blood and Induced Sputum in Patients With Stable Chronic Obstructive Pulmonary Disease

CHEST Journal ◽  
2016 ◽  
Vol 149 (4) ◽  
pp. A387 ◽  
Author(s):  
Caimei Tan ◽  
Huijuan Huang ◽  
Jianquan Zhang ◽  
Zhiyi He ◽  
Xiaoning Zhong ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Peripheral Blood ◽  
Low Dose ◽  
Term Treatment ◽  
Induced Sputum ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Long Term Treatment

Impact of long-term treatment with low-dose inhaled corticosteroids on the bone mineral density of chronic obstructive pulmonary disease patients: Aggravating or beneficial?

Respirology ◽  
2012 ◽  
Vol 18 (1) ◽  
pp. 147-153 ◽  
Author(s):  
ALEXANDROS G. MATHIOUDAKIS ◽  
STAVROULA G. AMANETOPOULOU ◽  
IOANNIS P. GIALMANIDIS ◽  
VICTORIA CHATZIMAVRIDOU-GRIGORIADOU ◽  
GERASIMOS SIASOS ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Chronic Obstructive Pulmonary Disease ◽  
Low Dose ◽  
Inhaled Corticosteroids ◽  
Term Treatment ◽  
Chronic Obstructive ◽  
Mineral Density ◽  
Obstructive Pulmonary Disease ◽  
Long Term Treatment

scholarly journals Effects of Low-Dose and Long-Term Treatment with Erythromycin on Interleukin-17 and Interleukin-23 in Peripheral Blood and Induced Sputum in Patients with Stable Chronic Obstructive Pulmonary Disease

2016 ◽  
Vol 2016 ◽  
pp. 1-11 ◽  
Author(s):  
Caimei Tan ◽  
Huijuan Huang ◽  
Jianquan Zhang ◽  
Zhiyi He ◽  
Xiaoning Zhong ◽  
...  
Keyword(s):  
Peripheral Blood ◽  
Treated Group ◽  
Term Treatment ◽  
Induced Sputum ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Copd Patients ◽  
Long Term Treatment ◽  
Group B

Objective.To study the effects of low-dose and long-term treatment with erythromycin on IL-17 and IL-23, in peripheral blood and induced sputum, in patients with stable chronic obstructive pulmonary disease (COPD).Methods. Patients were randomly divided into placebo-treated group, group A (12 months of additive treatment with erythromycin,N=18), and group B (6 months of additive treatment with erythromycin followed by 6 months of follow-up,N=18). Inflammatory cells in induced sputum, pulmonary function, and the 6-minute walk distance (6MWD) were analyzed. Concentrations of IL-17 and IL-23 in peripheral blood and sputum were measured using enzyme-linked immunosorbent assays.Results. After treatment, sputum and peripheral blood concentrations of IL-17 and IL-23 significantly decreased in groups A and B compared with placebo-treated group. There were no significant differences after erythromycin withdrawal at months 9 and 12 in group B compared with placebo-treated group. An increase in 6MWD was observed after treatment.Conclusions. Erythromycin was beneficial and reduced airway inflammation in COPD patients. Underlying mechanisms may involve inhibition of IL-17 and IL-23 mediated airway inflammation. COPD patients treated with erythromycin for 6 months experienced improved exercise capacity. Finally, treatment for 12 months may be more effective than treatment for 6 months.

Sign in / Sign up

Export Citation Format

Share Document